Fundraising FoxExor — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
PhaseV provides AI/ML-driven software for designing and optimizing clinical trials, including trial simulation, adaptive design, patient subgroup identification, and early endpoint detection.
AI & Machine LearningBiotechDigital HealthCambridge, US
Elad Berkman(Founder)in
Co-investorsAccelLionBirdViola VenturesExor VenturesInsight Partners
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechHealthtechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)inJosh Bilenker Jeff Engelman(Founder)
BoardKristina Burow(Director)inAli Satvat(Director)
Co-investorsAisling CapitalARCH Venture PartnersGV (Google Ventures)OrbiMedARC VENTURESCasdin Capital+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.